FMA
RNAC icon

FNY Managed Accounts’s Cartesian Therapeutics RNAC Stock Holding History

FNY Managed Accounts’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-93
Closed -$27K – 798
2017
Q4 		$27K Buy
+93
New +$40.6K 0.02% 119

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FNY Managed Accounts's RNAC Position: Q1 2018 in Review

FNY Managed Accounts sold out of Cartesian Therapeutics (RNAC) in Q1 2018, closing a stake of 93 shares — an estimated $27K sold.

FNY Managed Accounts first reported a position in RNAC in Q4 2017 and held it in 1 quarter. The position peaked at $27K in Q4 2017. 59 funds tracked by Wall St. Rank hold RNAC as of Q1 2018.

  • FNY Managed Accounts reported no remaining Cartesian Therapeutics position as of Q1 2018 after selling out during the quarter.
  • FNY Managed Accounts sold 93 Cartesian Therapeutics shares in Q1 2018, an estimated $27K.
  • FNY Managed Accounts first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Cartesian Therapeutics position peaked at $27K in Q4 2017.
  • 59 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.